Compound muscle action potential of whole-forearm flexors: A clinical biomarker for inclusion body myositis

IF 2 Q3 NEUROSCIENCES Clinical Neurophysiology Practice Pub Date : 2024-01-01 DOI:10.1016/j.cnp.2024.03.003

Tomoo Mano , Naohiko Iguchi , Naoki Iwasa , Nanami Yamada , Kazuma Sugie

{"title":"Compound muscle action potential of whole-forearm flexors: A clinical biomarker for inclusion body myositis","authors":"Tomoo Mano , Naohiko Iguchi , Naoki Iwasa , Nanami Yamada , Kazuma Sugie","doi":"10.1016/j.cnp.2024.03.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to investigate the potential of whole-forearm flexor muscle (WFFM) compound muscle action potential (CMAP) as a quantitative biomarker for inclusion body myositis (IBM) pathology.</p></div><div><h3>Methods</h3><p>We prospectively enrolled 14 consecutive patients (10 men and 4 women) diagnosed with IBM based on muscle biopsies. We evaluated the baseline-to-peak amplitude of the WFFM CMAP and other quantitative parameters, including grip and pinch strength, Inclusion Body Myositis Functional Rating Scale (IBMFRS) score, and other routine muscle CMAP amplitudes.</p></div><div><h3>Results</h3><p>The WFFM CMAP was strongly correlated with disease duration and the IBMFRS score. The WFFM CMAP on the more affected side was lower than that on the less affected side. Furthermore, grip power was strongly correlated with the WFFM CMAP, whereas lateral pinch strength was strongly correlated with the WFFM and first dorsal interosseous CMAPs. The 3-point pinch strength was also correlated with the WFFM CMAP.</p></div><div><h3>Conclusions</h3><p>This study demonstrates that the WFFM CMAP may serve as a biomarker of severity in IBM.</p></div><div><h3>Significance</h3><p>Identification of this biomarker can support drug development, diagnosis, prognosis, and treatment options for patients with IBM.</p></div>","PeriodicalId":45697,"journal":{"name":"Clinical Neurophysiology Practice","volume":"9 ","pages":"Pages 162-167"},"PeriodicalIF":2.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2467981X24000143/pdfft?md5=c5ee443e624833861e41f2e57e89ec24&pid=1-s2.0-S2467981X24000143-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neurophysiology Practice","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2467981X24000143","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This study aimed to investigate the potential of whole-forearm flexor muscle (WFFM) compound muscle action potential (CMAP) as a quantitative biomarker for inclusion body myositis (IBM) pathology.

Methods

We prospectively enrolled 14 consecutive patients (10 men and 4 women) diagnosed with IBM based on muscle biopsies. We evaluated the baseline-to-peak amplitude of the WFFM CMAP and other quantitative parameters, including grip and pinch strength, Inclusion Body Myositis Functional Rating Scale (IBMFRS) score, and other routine muscle CMAP amplitudes.

Results

The WFFM CMAP was strongly correlated with disease duration and the IBMFRS score. The WFFM CMAP on the more affected side was lower than that on the less affected side. Furthermore, grip power was strongly correlated with the WFFM CMAP, whereas lateral pinch strength was strongly correlated with the WFFM and first dorsal interosseous CMAPs. The 3-point pinch strength was also correlated with the WFFM CMAP.

Conclusions

This study demonstrates that the WFFM CMAP may serve as a biomarker of severity in IBM.

Significance

Identification of this biomarker can support drug development, diagnosis, prognosis, and treatment options for patients with IBM.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

全臂屈肌的复合肌肉动作电位：包涵体肌炎的临床生物标志物

目的：本研究旨在探讨全臂屈肌（WFFM）复合肌肉动作电位（CMAP）作为包涵体肌炎（IBM）病理学定量生物标记物的潜力。方法：我们前瞻性地连续招募了 14 名根据肌肉活检诊断为 IBM 的患者（10 名男性和 4 名女性）。结果WFFM CMAP与病程和IBMFRS评分密切相关。患侧的 WFFM CMAP 低于患侧。此外，握力与 WFFM CMAP 密切相关，而侧向捏力与 WFFM 和第一背侧骨间 CMAP 密切相关。结论本研究表明，WFFM CMAP 可作为 IBM 严重程度的生物标志物。重要意义确定该生物标志物有助于 IBM 患者的药物开发、诊断、预后和治疗方案的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Neurophysiology Practice NEUROSCIENCES-

CiteScore

3.90

自引率

0.00%

发文量

审稿时长

71 days

期刊介绍： Clinical Neurophysiology Practice (CNP) is a new Open Access journal that focuses on clinical practice issues in clinical neurophysiology including relevant new research, case reports or clinical series, normal values and didactic reviews. It is an official journal of the International Federation of Clinical Neurophysiology and complements Clinical Neurophysiology which focuses on innovative research in the specialty. It has a role in supporting established clinical practice, and an educational role for trainees, technicians and practitioners.